New developments in the treatment of castration resistant prostate cancer  

作　　者：Roxanne Wadia Daniel P Petrylak 

机构地区：[1]Department of Medicine, Smilow Cancer Center, Yale University School of Medicine, Yale Comprehensive Cancer Center, New Haven, Connecticut, USA

出　　处：《Asian Journal of Andrology》2014年第4期555-560,共6页亚洲男性学杂志（英文版）

摘　　要：In the past 5 years, the treatment and understanding of metastatic castrate resistant prostate cancer （CRPC） have improved dramatically. Our understanding of the mechanisms of castration resistance has allowed for the development of new drugs to target prostate cancer, and our understanding of genetic mutations may give us new tools with which to more accurately diagnose and be able to predict the course of this heterogeneous disease. This article summarizes the recent advances in the understanding of the development of CRPC, as well as the new drugs and targets, which have evolved from this basic research.In the past 5 years, the treatment and understanding of metastatic castrate resistant prostate cancer （CRPC） have improved dramatically. Our understanding of the mechanisms of castration resistance has allowed for the development of new drugs to target prostate cancer, and our understanding of genetic mutations may give us new tools with which to more accurately diagnose and be able to predict the course of this heterogeneous disease. This article summarizes the recent advances in the understanding of the development of CRPC, as well as the new drugs and targets, which have evolved from this basic research.

关 键 词：castration resistant prostate cancer ABIRATERONE enzalutamide chemotherapy DOCETAXEL CABAZITAXEL PSMA antibody 

分 类 号：Q78[生物学—分子生物学] S858.28[农业科学—临床兽医学]